Abiopharma

🔍 McGrane Ashley (Executive)

Company: ZoomInfo Technologies Inc. (GTM)

Report Date: 2026-05-01

Detailed Transactions and Holdings:

• Acquired 5,986 shares of Common Stock (Direct)
  Date: 2026-05-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 82,858.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 1,757 shares of Common Stock at $6.25 per share (Direct)
  Date: 2026-05-01 | Code: F | equity_swap_involved: 0 | shares_owned_after: 81,101.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 1,057 shares of Common Stock at $6.585 per share (Direct)
  Date: 2026-05-04 | Code: S | equity_swap_involved: 0 | shares_owned_after: 80,044.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 5,986 shares of Restricted Stock Units (Derivative)
  Date: 2026-05-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 59,867.00 | transaction_form_type: 4 | Footnotes: F1, F1, F4, F4

Footnotes:

• F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.
• F2: Reflects shares withheld to cover the Reporting Person's tax liability in connection with the vesting of the restricted stock units reported herein.
• F3: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.
• F4: The Reporting Person received an original grant of restricted stock units on October 22, 2024, which vest as follows: (a) 25% on November 1, 2025; and (b) the remainder of the award in equal quarterly installments during the 36 months following November 1, 2025.